Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: J Surg Oncol. 2021 Apr 24;124(3):308–316. doi: 10.1002/jso.26510

Table 1.

Baseline demographic and preoperative variables in R and BR PDAC patients who received NAT and underwent curative-intent pancreaticoduodenectomy.

Variable Overall cohort
(n = 273)
Event ≤6 months
(n = 64)
Event >6 month/no recurrence
(n = 209)
P-value
Age, yrs 65 (58–72) 65 (55–73) 66 (59–71) 0.259
Male gender 136 (50) 35(55) 101 (48) 0.373
White race 263 (96) 63 (98) 200 (96) 0.461
BMI, kg/m2 26 (23–30) 26 (23–30) 27 (23–30) 0.339
ASA class
1 1 (0.4) 0 (0) 1 (0.5)
2 33 (13) 2 (3) 31 (15) 0.080
3 214 (81) 56 (90) 158 (78)
4 16 (6) 4 (7) 12 (6)
CCI (age-adjusted) 5(4–5) 4(4–5) 5(4–6) 0.347
Radiologic stage at diagnosis
Resectable 78 (29) 62 (30) 16 (25) 0.470
Borderline resectable 195 (71) 147 (70) 48 (75)
EUS size, cm 2.8 (2.3–3.4) 3 (2.5–3.5) 2.8 (2.3–3.4) 0.135
CT size, cm 2.9 (2.2–3.5) 3.2 (2.7–3.8) 2.8 (2.1–3.3) 0.002
Vessel involvement 201 (73.9) 49 (76.6) 152 (73.1) 0.579
None 71 (26.1) 15 (23.4) 56 (26.9)
Venous 155 (57) 33 (51.6) 122 (58.7) 0.157
Arterial 10 (3.7) 2 (3.1) 8 (3.9)
Venous and arterial 36 (13.2) 14 (21.9) 22 (10.6)
Type of NAT
Gemcitabine based 211 (77) 47 (73) 164 (79)
5-FU based 45 (17) 11 (17) 34 (16) 0.531
Crossover 13 (4.8) 5 (7.8) 8 (3.8)
Other 4 (1.5) 1 (1.6) 3 (1.4)
Number of NAT cycles 3 (2–4) 3 (2–5) 3 (2–4) 0.719
Neoadjuvant radiotherapy 101 (37) 28 (44) 73 (35) 0.201
CA19–9 level, U/ml
Pre-NAT 201 (54–626) 472 (75–1469) 153 (49–413) 0.001
Post-NAT 43 (15–136) 71 (20–320) 39 (14–100) 0.005

Variables are presented as medians (interquartile range) and raw numbers (percentage). BMI: body mass index, ASA: American Society of Anesthesiology score, CCI: Charlson-comorbidity index, EUS: endoscopic ultrasound, CT: computed tomography, NAT: neoadjuvant treatment